Drugmakers race to capture Keytruda biosimilars as MSD shifts to SC

With Keytruda's patent expiring in 2028, multiple pharmaceutical companies including Samsung Bioepis, Formycon, Zydus, Celltrion, and Amgen are advancing biosimilar candidates, aiming to capture the market. Merck (MSD) is defending its market share by introducing a subcutaneous formulation of Keytruda, leveraging new technology to improve patient convenience and speed of administration.

This Wire brief sits within Fusion42's coverage of Biotech, and 2 sources have reported it.